Channing Der

Q: What Schools Are Affiliated With Channing Der

Channing Der is affiliated with the following schools: University of Texas Southwestern Medical Center, Harvard University, University of California, Irvine, University of Southern California, University of California, Los Angeles, Sanford Burnham Prebys Medical Discovery Institute, University of North Carolina at Chapel Hill, University of California, San Francisco

Channing Der's AcademicInfluence.com Rankings

Channing Der

Medical

#838

World Rank

#1096

Historical Rank

Oncology

#26

World Rank

#27

Historical Rank

medical Degrees

Download Badge

Medical

Channing Der's Degrees

Doctorate Medicine University of California, San Francisco
PhD Pharmacology University of California, San Francisco

Why Is Channing Der Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Channing Joseph Der is an American scientist and educator, and Sarah Graham Kenan Distinguished Professor of Pharmacology, at UNC Lineberger Comprehensive Cancer Center. Der is a Fellow of the American Association for the Advancement of Science, He is recognized for his work with the Ras oncoprotein and its role in human oncogenesis.

(See a Problem?)

Channing Der's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (2012) (2913)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007) (2650)
GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors (2005) (1748)
Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts (1997) (1653)
The Ras superfamily at a glance (2005) (1403)
Drugging the undruggable RAS: Mission Possible? (2014) (1356)
Increasing complexity of Ras signaling (1998) (1096)
Understanding Ras: 'it ain't over 'til it's over'. (2000) (825)
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 (2021) (811)
Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K (1997) (778)
Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation (1995) (714)
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? (2010) (701)
p21ras is modified by a farnesyl isoprenoid. (1989) (699)
Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. (1982) (686)
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein (1993) (679)
Rho-family GTPases: it's not only Rac and Rho (and I like it) (2004) (648)
Increasing Complexity of the Ras Signaling Pathway* (1998) (602)
Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. (1997) (585)
RAS isoforms and mutations in cancer at a glance (2016) (566)
ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix (2003) (540)
KRAS: feeding pancreatic cancer proliferation. (2014) (523)
Biological and biochemical properties of human ras H genes mutated at codon 61 (1986) (497)
GTP-binding mutants of rab1 and rab2 are potent inhibitors of vesicular transport from the endoplasmic reticulum to the Golgi complex (1992) (495)
Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways (1997) (484)
The Mitogen-activated Protein Kinase Phosphatases PAC1, MKP-1, and MKP-2 Have Unique Substrate Specificities and Reduced Activity in Vivo toward the ERK2 sevenmaker Mutation (*) (1996) (473)
Distinct requirements for Ras oncogenesis in human versus mouse cells. (2002) (465)
Ras history (2010) (459)
Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. (1988) (451)
Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. (1992) (451)
The dark side of Ras: regulation of apoptosis (2003) (436)
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. (2018) (434)
The Ras branch of small GTPases: Ras family members don't fall far from the tree. (2000) (433)
Oncogenic Ha-Ras-induced Signaling Activates NF-κB Transcriptional Activity, Which Is Required for Cellular Transformation* (1997) (405)
Signaling Interplay in Ras Superfamily Function (2005) (394)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer (2019) (380)
Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*) (1995) (379)
Inhibition of Ras for cancer treatment: the search continues. (2011) (378)
Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. (2005) (370)
Rab1b regulates vesicular transport between the endoplasmic reticulum and successive Golgi compartments (1991) (370)
Rho family proteins and Ras transformation: the RHOad less traveled gets congested (1998) (370)
Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation (1996) (367)
Activation of RalA is critical for Ras-induced tumorigenesis of human cells. (2005) (364)
Human cell hybrids: analysis of transformation and tumorigenicity. (1982) (349)
The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. (2001) (346)
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? (2004) (345)
Lck regulates Vav activation of members of the Rho family of GTPases (1997) (343)
Honokiol, a Small Molecular Weight Natural Product, Inhibits Angiogenesis in Vitro and Tumor Growth in Vivo* (2003) (341)
Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease (2014) (341)
Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism (2002) (339)
The coupling of α6β4 integrin to Ras–MAP kinase pathways mediated by Shc controls keratinocyte proliferation (1997) (331)
Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification* (2008) (328)
Ras and Rho regulation of the cell cycle and oncogenesis. (2001) (323)
Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia (1995) (320)
Integration of Rac-dependent Regulation of Cyclin D1 Transcription through a Nuclear Factor-κB-dependent Pathway* (1999) (319)
Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation (1989) (302)
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. (1990) (299)
Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases* (2007) (299)
Role of a Mitogen-activated Protein Kinase Pathway in the Induction of Phase II Detoxifying Enzymes by Chemicals* (1999) (295)
Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? (1997) (292)
Oncogenic Ras and its role in tumor cell invasion and metastasis. (2004) (282)
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? (2015) (278)
Dbl family proteins. (1997) (275)
Vav2 Is an Activator of Cdc42, Rac1, and RhoA* (2000) (271)
Critical role of Rho in cell transformation by oncogenic Ras. (1995) (267)
Drugging RAS: Know the enemy (2017) (266)
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? (2010) (256)
Regulation of RasGRP via a Phorbol Ester-Responsive C1 Domain (1998) (253)
Rnd Proteins Function as RhoA Antagonists by Activating p190 RhoGAP (2003) (249)
Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells (2006) (238)
Ligand-dependent dynamics and intramolecular signaling in a PDZ domain. (2004) (228)
Guanine nucleotide exchange factors: Activators of the Ras superfamily of proteins (1995) (225)
Structural basis for the selective activation of Rho GTPases by Dbl exchange factors (2002) (223)
Two Distinct Raf Domains Mediate Interaction with Ras (*) (1995) (223)
Ras Family Signaling: Therapeutic Targeting (2002) (218)
A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma (2010) (214)
Emerging concepts in the Ras superfamily of GTP‐binding proteins (1993) (210)
Protein prenylation: more than just glue? (1992) (206)
K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. (2007) (206)
Increasing complexity of Ras signal transduction: involvement of Rho family proteins. (1998) (204)
Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis (2004) (203)
Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. (2010) (200)
Biological assays for Ras transformation. (1995) (196)
Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases. (1994) (189)
Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation (2004) (188)
The Ras-related Protein Rheb Is Farnesylated and Antagonizes Ras Signaling and Transformation* (1997) (184)
Leukemia-Associated Rho Guanine Nucleotide Exchange Factor Promotes Gαq-Coupled Activation of RhoA (2002) (183)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. (2016) (182)
Searching for the elusive targets of farnesyltransferase inhibitors (2003) (182)
Splice Variants of Intersectin Are Components of the Endocytic Machinery in Neurons and Nonneuronal Cells* (1999) (181)
Integrin-mediated activation of mitogen-activated protein (MAP) or extracellular signal-related kinase kinase (MEK) and kinase is independent of ras (1996) (177)
The Ras signal transduction pathway (1994) (176)
Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein (1992) (174)
Aberrant function of the Ras signal transduction pathway in human breast cancer (1995) (172)
Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase (1996) (171)
P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. (2011) (166)
KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer (2009) (165)
RERG Is a Novel ras-related, Estrogen-regulated and Growth-inhibitory Gene in Breast Cancer* (2001) (163)
The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. (2006) (160)
Isolation of a NCK-associated Kinase, PRK2, an SH3-binding Protein and Potential Effector of Rho Protein Signaling* (1996) (158)
Isoprenoid modification of rab proteins terminating in CC or CXC motifs. (1991) (155)
R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl- 2 suppressible mechanism (1995) (155)
Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. (1996) (154)
Altered gene products are associated with activation of cellular rasK genes in human lung and colon carcinomas (1983) (152)
Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells (2004) (151)
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment (2016) (149)
Identification and characterization of Src SH3 ligands from phage-displayed random peptide libraries. (1994) (146)
Loss of Transgelin in Breast and Colon Tumors and in RIE-1 Cells by Ras Deregulation of Gene Expression through Raf-independent Pathways* (2002) (145)
DLC‐1 suppresses non‐small cell lung cancer growth and invasion by RhoGAP‐dependent and independent mechanisms (2008) (140)
Ras Interaction with Two Distinct Binding Domains in Raf-1 5 Be Required for Ras Transformation (*) (1996) (139)
Dbl and Vav mediate transformation via mitogen-activated protein kinase pathways that are distinct from those activated by oncogenic Ras (1994) (137)
Oncogenic Neu/ErbB-2 Increases Ets, AP-1, and NF-B-dependent Gene Expression, and Inhibiting Ets Activation Blocks Neu-mediated Cellular Transformation (*) (1996) (136)
Protein prenylation: key to ras function and cancer intervention? (1992) (136)
Oncogenic Ras Blocks Anoikis by Activation of a Novel Effector Pathway Independent of Phosphatidylinositol 3-Kinase (2001) (135)
Activation of the cellular proto-oncogene product p21Ras by addition of a myristylation signal. (1989) (135)
Farnesyltransferase inhibitors: promises and realities. (2002) (131)
XPLN, a Guanine Nucleotide Exchange Factor for RhoA and RhoB, But Not RhoC* (2002) (131)
Leukemia-associated Rho Guanine Nucleotide Exchange Factor, a Dbl Family Protein Found Mutated in Leukemia, Causes Transformation by Activation of RhoA* (2001) (130)
Oncogenic Ras can induce transcriptional activation through a variety of promoter elements, including tandem c-Ets-2 binding sites. (1994) (129)
A Raf-independent Epidermal Growth Factor Receptor Autocrine Loop Is Necessary for Ras Transformation of Rat Intestinal Epithelial Cells* (1997) (129)
Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity. (1994) (126)
14-3-3 ζ Negatively Regulates Raf-1 Activity by Interactions with the Raf-1 Cysteine-rich Domain* (1997) (124)
The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. (1994) (122)
Isoprenoid modification and plasma membrane association: critical factors for ras oncogenicity. (1991) (122)
Rap1A is a substrate for cyclic AMP-dependent protein kinase in human neutrophils. (1991) (122)
RhoG Signals in Parallel with Rac1 and Cdc42* (2002) (120)
ras-induced neuronal differentiation of PC12 cells: possible involvement of fos and jun (1989) (120)
The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways (2001) (119)
M-Ras/R-Ras3, a Transforming Ras Protein Regulated by Sos1, GRF1, and p120 Ras GTPase-activating Protein, Interacts with the Putative Ras Effector AF6* (1999) (117)
ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. (2012) (116)
R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells. (1994) (116)
The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. (2011) (114)
SGEF, a RhoG guanine nucleotide exchange factor that stimulates macropinocytosis. (2004) (114)
Rho Family GTPases Regulate Mammary Epithelium Cell Growth and Metastasis Through Distinguishable Pathways (2001) (113)
The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation. (1997) (110)
Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA (2009) (110)
Ral and Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion. (2014) (110)
Activation of ras genes in human tumors does not affect localization, modification, or nucleotide binding properties of p21 (1984) (109)
Persistent Signaling by Dysregulated Thrombin Receptor Trafficking Promotes Breast Carcinoma Cell Invasion (2004) (109)
Molecular Basis for Rho GTPase Signaling Specificity (2004) (109)
GTP binding by class II transactivator: role in nuclear import. (1999) (109)
Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. (2008) (108)
The ras superfamily of GTP‐binding proteins: guidelines on nomenclature (1992) (108)
Stimulation of p38 Phosphorylation and Activity by Arachidonic Acid in HeLa Cells, HL60 Promyelocytic Leukemic Cells, and Human Neutrophils (1998) (108)
p120 GAP Modulates Ras Activation of Jun Kinases and Transformation* (1997) (108)
A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain. (1996) (107)
Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility (2009) (106)
Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation (1994) (105)
Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth (1999) (104)
Dependence of Dbl and Dbs Transformation on MEK and NF-κB Activation (1999) (103)
RasGRP4 Is a Novel Ras Activator Isolated from Acute Myeloid Leukemia* (2002) (101)
Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia (2000) (100)
Activation of Phospholipase C-ε by Heterotrimeric G Protein βγ-Subunits* (2001) (100)
The role of wild type RAS isoforms in cancer. (2016) (100)
Release of autoinhibition of ASEF by APC leads to CDC42 activation and tumor suppression (2007) (100)
Biological assays for cellular transformation. (1994) (99)
Molecular basis for Rac1 recognition by guanine nucleotide exchange factors (2001) (97)
Identification of residues critical for Ras(17N) growth-inhibitory phenotype and for Ras interaction with guanine nucleotide exchange factors (1994) (97)
Activated or dominant inhibitory mutants of Rap1A decrease the oxidative burst of Epstein-Barr virus-transformed human B lymphocytes. (1994) (97)
Expression Cloning of lsc, a Novel Oncogene with Structural Similarities to the Dbl Family of Guanine Nucleotide Exchange Factors* (1996) (97)
Role of MAP Kinases in the 1,25-Dihydroxyvitamin D3-induced Transactivation of the Rat Cytochrome P450C24 (CYP24) Promoter (2002) (96)
Targeting RAS-mutant cancers: is ERK the key? (2015) (95)
Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame. (2014) (94)
rasH mutants deficient in GTP binding (1986) (94)
Elucidation of Binding Determinants and Functional Consequences of Ras/Raf-Cysteine-rich Domain Interactions* (2000) (94)
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. (2018) (93)
Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. (2010) (93)
Raf-independent Deregulation of p38 and JNK Mitogen-activated Protein Kinases Are Critical for Ras Transformation* (2002) (92)
Transforming Potential of Dbl Family Proteins Correlates with Transcription from the Cyclin D1 Promoter but Not with Activation of Jun NH2-terminal Kinase, p38/Mpk2, Serum Response Factor, or c-Jun* (1998) (91)
Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. (1996) (91)
Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells. (1986) (91)
Ras-mediated Loss of the Pro-apoptotic Response Protein Par-4 Is Mediated by DNA Hypermethylation through Raf-independent and Raf-dependent Signaling Cascades in Epithelial Cells* (2005) (91)
Differential Requirement of CAAX-mediated Posttranslational Processing for Rheb Localization and Signaling (2009) (91)
Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma. (2017) (90)
Novel determinants of H-Ras plasma membrane localization and transformation. (1996) (90)
Rho GTPase-dependent transformation by G protein-coupled receptors (2001) (90)
Quantitative Analysis of the Effect of Phosphoinositide Interactions on the Function of Dbl Family Proteins* (2001) (89)
The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein (1991) (89)
Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration* (2013) (89)
Atypical Mechanism of Regulation of the Wrch-1 Rho Family Small GTPase (2004) (89)
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. (2007) (88)
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. (2019) (86)
Transforming Activity of the Rho Family GTPase, Wrch-1, a Wnt-regulated Cdc42 Homolog, Is Dependent on a Novel Carboxyl-terminal Palmitoylation Motif* (2005) (86)
Geranylgeranyltransferase I Inhibitors Target RalB To Inhibit Anchorage-Dependent Growth and Induce Apoptosis and RalA To Inhibit Anchorage-Independent Growth (2007) (84)
Oncogene activation of human keratin 18 transcription via the Ras signal transduction pathway. (1994) (82)
Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. (1996) (80)
Mas Oncogene Signaling and Transformation Require the Small GTP-Binding Protein Rac (1998) (79)
Activation and involvement of Ral GTPases in colorectal cancer. (2011) (78)
Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function. (1996) (77)
Oncogenic Activity of Ect2 Is Regulated through Protein Kinase Cι-mediated Phosphorylation* (2010) (77)
The ras/cholesterol connection: implications for ras oncogenicity. (1992) (75)
A tumor-specific membrane phosphoprotein marker in human cell hybrids (1981) (75)
Identification of a Novel RalGDS-related Protein as a Candidate Effector for Ras and Rap1* (1996) (74)
K-Ras Promotes Angiogenesis Mediated by Immortalized Human Pancreatic Epithelial Cells through Mitogen-Activated Protein Kinase Signaling Pathways (2009) (73)
G2A is an oncogenic G protein-coupled receptor (2000) (73)
Guanine nucleotide exchange factors: Activators of Ras superfamily proteins (1995) (73)
Cellular N-Ras Promotes Cell Survival by Downregulation of Jun N-Terminal Protein Kinase and p38 (2002) (70)
Differential regulation of SHC proteins by nerve growth factor in sensory neurons and PC12 cells (1998) (70)
Polylysine domain of K-ras 4B protein is crucial for malignant transformation. (1994) (70)
Integrin-mediated Activation of MEK and Mitogen-activated Protein Kinase Is Independent of Ras* (1996) (68)
p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities (2009) (68)
TC21 and Ras share indistinguishable transforming and differentiating activities (1999) (67)
Ras (CXXX) and Rab (CC/CXC) prenylation signal sequences are unique and functionally distinct. (1992) (67)
Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation. (1995) (67)
Lack of correlation between the decreased expression of cell surface LETS protein and tumorigenicity in human cell hybrids (1978) (67)
A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. (2017) (66)
A Non-farnesylated Ha-Ras Protein Can Be Palmitoylated and Trigger Potent Differentiation and Transformation* (1999) (66)
Ras-15A protein shares highly similar dominant-negative biological properties with Ras-17N and forms a stable, guanine-nucleotide resistant complex with CDC25 exchange factor. (1994) (66)
Regulation of Rnd3 localization and function by protein kinase C alpha-mediated phosphorylation. (2009) (66)
TC21 causes transformation by Raf-independent signaling pathways (1996) (65)
Interferon Regulatory Factor 7 Is Associated with Epstein-Barr Virus-Transformed Central Nervous System Lymphoma and Has Oncogenic Properties (2004) (65)
Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 Isoform* (2009) (64)
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. (2020) (64)
Critical and Distinct Roles of Amino- and Carboxyl-terminal Sequences in Regulation of the Biological Activity of the Chp Atypical Rho GTPase* (2005) (63)
Effects of Structure of Rho GTPase-activating Protein DLC-1 on Cell Morphology and Migration*S⃞ (2008) (62)
Identification and Characterization of Rain, a Novel Ras-interacting Protein with a Unique Subcellular Localization* (2004) (62)
Targeting signal transduction in pancreatic cancer treatment (2007) (62)
Expression of activated RAF accelerates cell differentiation and RB protein down-regulation but not hypophosphorylation. (1994) (61)
Involvement of Fibroblast Growth Factor Receptor 2 Isoform Switching in Mammary Oncogenesis (2008) (60)
Opposing Roles of the Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Cascades in Ras-Mediated Downregulation of Tropomyosin (2002) (60)
Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade (1998) (59)
The RalB Small GTPase Mediates Formation of Invadopodia through a GTPase-Activating Protein-Independent Function of the RalBP1/RLIP76 Effector (2012) (59)
CDC42 and FGD1 Cause Distinct Signaling and Transforming Activities (1998) (58)
Differential antagonism of Ras biological activity by catalytic and Src homology domains of Ras GTPase activation protein. (1993) (58)
Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. (2019) (58)
RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. (2002) (58)
Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF (1999) (57)
R-Ras is regulated by activators and effectors distinct from those that control Ras function (1997) (56)
Involvement of NH2-terminal Sequences in the Negative Regulation of Vav Signaling and Transforming Activity* (1999) (56)
Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells (1999) (56)
Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers. (2016) (55)
Computational design of chemogenetic and optogenetic split proteins (2018) (55)
Involvement of the Switch 2 Domain of Ras in Its Interaction with Guanine Nucleotide Exchange Factors (*) (1996) (55)
The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation. (2013) (55)
Ras effector switching promotes divergent cell fates in C. elegans vulval patterning. (2011) (55)
Dissection of Ras-Dependent Signaling Pathways Controlling Aggressive Tumor Growth of Human Fibrosarcoma Cells: Evidence for a Potential Novel Pathway (2000) (54)
Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. (2013) (54)
Requirement For C-terminal Sequences in Regulation of Ect2 Guanine Nucleotide Exchange Specificity and Transformation* (2004) (54)
Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function. (2001) (53)
Substrate Trapping Proteomics Reveals Targets of the βTrCP2/FBXW11 Ubiquitin Ligase (2014) (53)
Involvement of Phosphatidylinositol 3-Kinase, but Not RalGDS, in TC21/R-Ras2-mediated Transformation* (2002) (53)
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers (2020) (52)
Citron Kinase, a RhoA Effector, Enhances HIV‐1 Virion Production by Modulating Exocytosis (2006) (52)
Cancer: Drug for an 'undruggable' protein (2013) (52)
Aberrant Overexpression of the Rgl2 Ral Small GTPase-specific Guanine Nucleotide Exchange Factor Promotes Pancreatic Cancer Growth through Ral-dependent and Ral-independent Mechanisms* (2010) (52)
P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils (2014) (52)
Critical but Distinct Roles for the Pleckstrin Homology and Cysteine-Rich Domains as Positive Modulators of Vav2 Signaling and Transformation (2002) (52)
Auto-inhibition of the Dbl Family Protein Tim by an N-terminal Helical Motif* (2007) (51)
CRL4A-FBXW5–mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth (2013) (51)
Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers (2014) (48)
Altered guanine nucleotide binding and H-ras transforming and differentiating activities (1988) (47)
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers (2020) (47)
Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down. (2016) (47)
RETRACTED: RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress (2006) (47)
Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells (2004) (46)
Biochemical characterization of baculovirus-expressed rap1A/Krev-1 and its regulation by GTPase-activating proteins (1990) (45)
Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies (2017) (43)
Regulator of G-Protein Signaling 14 (RGS14) Is a Selective H-Ras Effector (2009) (43)
TEM4 is a junctional Rho GEF required for cell–cell adhesion, monolayer integrity and barrier function (2013) (42)
Biological and structural characterization of a Ras transforming mutation at the phenylalanine-156 residue, which is conserved in all members of the Ras superfamily. (1995) (41)
The Insert Region of Rac1 Is Essential for Membrane Ruffling but Not Cellular Transformation (2001) (40)
Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells (2010) (40)
Multiple sequence elements facilitate Chp Rho GTPase subcellular location, membrane association, and transforming activity. (2006) (39)
Analysis of Ras protein expression in mammalian cells. (1995) (38)
The raf inhibitor paradox: unexpected consequences of targeted drugs. (2010) (38)
ras Proto-Oncogene Activation in Human Malignancy (1995) (37)
Modulation of HIV-1 Replication by a Novel RhoA Effector Activity1 (2000) (36)
Monoclonal antibody specific for an activated RAS protein. (1986) (36)
Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth (2007) (36)
Structure and biological effects of lipid modifications on proteins (1992) (36)
Dependence of Dbl and Dbs transformation on MEK and NF-kappaB activation. (1999) (36)
p68RacGAP Is a Novel GTPase-activating Protein That Interacts with Vascular Endothelial Zinc Finger-1 and Modulates Endothelial Cell Capillary Formation* (2004) (35)
RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis (2011) (35)
Phosphorylation by Protein Kinase Cα Regulates RalB Small GTPase Protein Activation, Subcellular Localization, and Effector Utilization* (2012) (34)
The ect2 rho Guanine nucleotide exchange factor is essential for early mouse development and normal cell cytokinesis and migration. (2011) (34)
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer (2019) (34)
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 (2016) (33)
Divergent Roles of CAAX Motif-signaled Posttranslational Modifications in the Regulation and Subcellular Localization of Ral GTPases* (2015) (32)
Ras signaling, deregulation of gene expression and oncogenesis. (2003) (32)
RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress (2016) (31)
Ras Inactivation of the Retinoblastoma Pathway by Distinct Mechanisms in NIH 3T3 Fibroblast and RIE-1 Epithelial Cells* (2000) (31)
Differential involvement of RalA and RalB in colorectal cancer (2012) (31)
Critical Role of the Pleckstrin Homology and Cysteine-rich Domains in Vav Signaling and Transforming Activity* (2002) (31)
rek, a Gene Expressed in Retina and Brain, Encodes a Receptor Tyrosine Kinase of the Axl/Tyro3 Family* (1996) (30)
Critical Role of the Pleckstrin Homology Domain in Dbs Signaling and Growth Regulation* (2003) (29)
Real-time in vitro measurement of intrinsic and Ras GAP-mediated GTP hydrolysis. (2006) (29)
Filling GAPs in our knowledge: ARHGAP11A and RACGAP1 act as oncogenes in basal-like breast cancers (2018) (29)
Biochemical analyses of the Wrch atypical Rho family GTPases. (2006) (29)
Real-time in vitro measurement of GTP hydrolysis. (2005) (29)
Alterations in the extracellular matrix organization associated with the reexpression of tumorigenicity in human cell hybrids (1980) (28)
Prenoids and palmitate: lipids that control the biological activity of Ras proteins. (1992) (27)
Activation of phospholipase C-epsilon by heterotrimeric G protein betagamma-subunits. (2001) (27)
A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation* (2017) (27)
The Src Homology 2 and Phosphotyrosine Binding Domains of the ShcC Adaptor Protein Function as Inhibitors of Mitogenic Signaling by the Epidermal Growth Factor Receptor* (1998) (27)
Cellular oncogenes and human carcinogenesis. (1987) (26)
ROCK 1 and ROCK 2 are Required for Non-Small Cell Lung Cancer Anchorage-Independent Growth and Invasion (2012) (26)
Role of MLK3-mediated Activation of p70 S6 Kinase in Rac1 Transformation* (2002) (25)
Vav transformation requires activation of multiple GTPases and regulation of gene expression. (2004) (25)
CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer (2015) (25)
Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. (2006) (24)
Posttranslational lipid modification of Rho family small GTPases. (2012) (24)
Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells. (2003) (24)
Regulation of lymphotoxin production by the p21ras-raf-MEK-ERK cascade in PHA/PMA-stimulated Jurkat cells. (1999) (24)
Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma* (2016) (24)
The six amino-terminal amino acids of p60src are sufficient to cause myristylation of p21v-ras (1988) (24)
Oncogenic Activation of Ras Proteins (1993) (24)
Identification of a Novel Actin-Binding Domain within the Rho Guanine Nucleotide Exchange Factor TEM4 (2012) (23)
Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation. (2010) (23)
RAS and RHO family GTPase mutations in cancer: twin sons of different mothers? (2020) (23)
Genetic and pharmacologic dissection of Ras effector utilization in oncogenesis. (2006) (23)
Characterization of RERG: an estrogen-regulated tumor suppressor gene. (2006) (22)
Stopping Ras in Its Tracks (2007) (22)
TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling (2010) (22)
ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma (2016) (21)
Role of the pleckstrin homology domain in intersectin-L Dbl homology domain activation of Cdc42 and signaling. (2003) (21)
The ras family of oncogenes. (1989) (20)
Expression of ras proto‐oncogenes in the dunning R3327 rat prostatic adenocarcinoma system (1988) (20)
Use of Caenorhabditis elegans to evaluate inhibitors of Ras function in vivo. (2008) (20)
Binding Specificity and Mutational Analysis of the Phosphotyrosine Binding Domain of the Brain-specific Adaptor Protein ShcC (*) (1996) (20)
The RAF inhibitor paradox revisited. (2012) (20)
Mist1+ gastric isthmus stem cells are regulated by Wnt5a and expand in response to injury and inflammation in mice (2020) (20)
Analysis of function and regulation of proteins that mediate signal transduction by use of lipid-modified plasma membrane-targeting sequences. (2000) (20)
Ras-driven transformation of human nestin-positive pancreatic epithelial cells. (2008) (19)
Blocking autophagy to starve pancreatic cancer (2019) (19)
Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation (2013) (19)
The RhoGEF TEM4 Regulates Endothelial Cell Migration by Suppressing Actomyosin Contractility (2013) (18)
The carboxyl-terminal CXXX sequence of Gi alpha, but not Rab5 or Rab11, supports Ras processing and transforming activity. (1993) (18)
Alternate mechanisms of ras activation are complementary and favor and formation of ras-GTP. (1992) (18)
The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction. (2021) (17)
Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability (2017) (17)
Redundant Canonical and Noncanonical Caenorhabditis elegans p21-Activated Kinase Signaling Governs Distal Tip Cell Migrations (2013) (16)
Selective deficiency in protein kinase C isoenzyme expression and inadequacy in mitogen-activated protein kinase activation in cord blood T cells. (2003) (16)
KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. (2021) (16)
Cytoskeletal and transmembrane interactions in the expression of tumorigenicity in human cell hybrids. (1981) (16)
Ras‐mediated intestinal epithelial cell transformation requires cyclooxygenase‐2‐induced prostaglandin E2 signaling (2007) (15)
The G 12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis (2006) (15)
RAS Mutations Are Not Created Equal. (2019) (15)
Analyses of transforming activity of Rho family activators. (2000) (14)
Identity of HeLa cell determinants acquired by vesicular stomatitis virus with a tumor antigen. (1983) (14)
Are all KRAS mutations created equal? (2011) (14)
Mutant and wild-type Ras: co-conspirators in cancer. (2013) (13)
Prenylation analysis of bacterially expressed and insect cell-expressed Ras and Ras-related proteins. (1995) (13)
Seeing is believing: Ras dimers observed in live cells (2015) (12)
Faculty Opinions recommendation of RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. (2010) (12)
Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders (2020) (11)
Activation of ras oncogenes in chemically transformed BALB/MK‐2 mouse keratinocytes (1989) (11)
Transcriptional activation analysis of oncogene function. (1994) (11)
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment (2021) (11)
Alterations in transformation efficiency by the ADPRT-inhibitor 3-aminobenzamide are oncogene specific. (1989) (10)
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer (2021) (10)
Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors. (2021) (10)
Tools to study the function of the Ras-related, estrogen-regulated growth inhibitor in breast cancer. (2008) (9)
RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress (2012) (8)
Targeting proteins to membranes using signal sequences for lipid modification. (1995) (8)
Rho Family GTPases and Cellular Transformation (2013) (8)
Targeting the Raf-MEK-ERK Mitogen-Activated Protein Kinase Cascade for the Treatment of RAS Mutant Cancers (2014) (8)
The C. elegans Chp/Wrch Ortholog CHW-1 Contributes to LIN-18/Ryk and LIN-17/Frizzled Signaling in Cell Polarity (2015) (8)
Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers. (2013) (8)
Erratum: Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras (Journal of Biological Chemistry (1996) 271 (18122-18127)) (1996) (8)
GTP-binding protein-stimulated phospholipase C and phospholipase D activities in ras-transformed NIH 3T3 fibroblasts. (1990) (8)
Transformation by a nucleotide-activated P2Y receptor is mediated by activation of Gαi, Gαq and Rho-dependent signaling pathways (2010) (8)
Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition (2009) (8)
Abstract 5492: Inhibition of ERK MAPK signaling increases pancreatic cancer dependency on autophagy (2018) (8)
Inhibitors of the ROCK serine/threonine kinases: key effectors of the RhoA small GTPase. (2013) (7)
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. (2020) (7)
Mechanisms of targeted therapy resistance take a de-TOR. (2013) (7)
Lipid Modification of Ras Superfamily GTPases: Not Just Membrane Glue (2011) (7)
Ras-Mediated Deregulation of Gene Expression and Contribution to Oncogenesis (2003) (6)
Identification of Ras-regulated genes by representational difference analysis. (2001) (6)
Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth (2021) (6)
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer. (2022) (5)
Genome-wide DNA methylation analysis of KRAS mutant cell lines (2020) (5)
Binge Drinking: Macropinocytosis Promotes Tumorigenic Growth of RAS-Mutant Cancers. (2020) (5)
Farnesyltransferase and Geranylgeranyltransferase Inhibitors: The Saga Continues (2000) (5)
Cellular assays of oncogene transformation (2006) (5)
CD45 and Src-related protein tyrosine kinases regulate the T cell response to phorbol esters. (1998) (5)
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer (2020) (5)
Analyses of TC21/R-Ras2 signaling and biological activity. (2001) (5)
Characterization of an Engineered Src Kinase to Study Src Signaling and Biology. (2016) (5)
RhoGAP DLC-1 tumor suppression and aberrant Rho GTPase activation in lung cancer (2006) (4)
Faculty Opinions recommendation of Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. (2008) (4)
Characterization of TR‐107, a novel chemical activator of the human mitochondrial protease ClpP (2022) (4)
Inhibitors of the Ras superfamily G-proteins (2013) (4)
Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. (2022) (4)
Ras Signaling and Transformation (2000) (4)
Functional and biological heterogeneity of KRASQ61 mutations (2022) (4)
Methods in Enzymology: Preface (2006) (4)
RAS Family GTPases (2006) (4)
Erratum: RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress (Current Biology (2012) 22(22) (2186–2187)(S0960982206024316)(10.1016/j.cub.2006.10.056)) (2016) (4)
Activation of cellular p21 ras by myristoylation (1989) (4)
Mutant RAS Calms Stressed-Out Cancer Cells. (2017) (4)
cause tumorigenic transformation . kinase-independent pathways is sufficient to Raf / mitogen-activated protein Oncogenic Ras activation of (1996) (3)
Overview of Rho GTPase History (2010) (3)
Farnesyltransferase Inhibitors Anti-Ras or Anticancer Drugs? (2000) (3)
GTPases regulating membrane targeting and fusion (2005) (3)
Rho Family Proteins (2014) (3)
Role of R-Ras in Cell Growth (2010) (3)
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. (2022) (3)
The roles of ras family small GTPases in breast cancer (2010) (3)
Raf-independent deregulation of p 38 and JNK kinases are critical for Ras transformation (2002) (3)
Silencing of oncogenic KRAS by mutant-selective small interfering RNA (2020) (3)
Faculty Opinions recommendation of Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. (2005) (2)
Inhibitors of the Ras superfamily of small G-proteins. Preface. (2013) (2)
Cell biology: GTPase traffic control (2000) (2)
RHOA takes the RHOad less traveled to cancer. (2022) (2)
Targeting Ras for Anticancer Drug Discovery (2010) (2)
Farnesyltransferase inhibitors: Anti-Ras drugs for cancer treatment (1996) (2)
Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen (2021) (2)
Substrate Trapping Proteomics Reveals Targets of the (cid:2) TrCP2/FBXW11 Ubiquitin Ligase (2014) (1)
ANTI-RAS STRATEGIES FOR CANCER TREATMENT (2006) (1)
Mutational Activation of KRAS and BRAF in Colorectal Cancer (2013) (1)
Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers. (2023) (1)
Proteins involved in transport (1995) (1)
Abstract 3508: Separate and combined effects of caloric restriction mimetics and autophagy inhibition on KRAS-driven pancreatic adenocarcinoma (2018) (1)
Abstract B15: CRISPR/Cas9 genetic screen identifies novel therapeutic strategies for treating HRAS mutant HNSCC with farnesyltransferase inhibitors (FTIs) (2020) (1)
Cloning and characterization of proteins that bind the sh3 domains of the nck adaptor protein (1996) (1)
Small GTPases in disease (2008) (1)
GTPases regulating membrane dynamics (2005) (1)
Regulation of Rnd3 Localization and Function By PKC α -Mediated Phosphorylation (2010) (1)
ras and its relatives. (1989) (1)
Type of Melanoma Mitogen-Activated Protein Kinase Signaling Shows a New Lack of Extracellular Signal-Regulated Kinase (2007) (1)
KRASG12R-Independent Macropinocytosis in Pancreatic Cancer. (2022) (1)
Ultrastructure of Human Pancreatic Cancer Cells Treated with a TBK1 Inhibitor (2019) (1)
Abstract SY20-02: Inhibitor combinations targeting KRAS effector signaling inKRAS-mutant pancreatic cancer (2018) (1)
Activation of cellular p21ras by myristoylation. (1989) (1)
Facile real time detection of membrane colocalization of RAS superfamily GTPase proteins in living cells (2018) (1)
Abstract B32: Silencing of oncogenic KRAS by a mutant-favoring short interfering RNA (2020) (1)
Faculty Opinions recommendation of Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. (2012) (0)
Abstract B13: Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma (2020) (0)
Abstract 4851: Improving the efficacy of dual ERK-MAPK and autophagy inhibition as a therapeutic strategy for pancreatic ductal adenocarcinoma (2023) (0)
Resource A Landscape of Therapeut ic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution Graphical (0)
Oncogenic Ha-Ras-induced Signaling Activates NF- (cid:107) B Transcriptional Activity, Which Is Required for Cellular Transformation* (1997) (0)
KRAS Suppression-Induced Degradation of MYC is Antagonized by a MEK5-ERK5 Compensatory Mechanism (2018) (0)
Erratum: Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells (Journal of Chemical Biochemistry (2000) 275 (40916-40924)) (2001) (0)
Farnesyltransferase and Geranylgeranyltransferase Inhibitors (2001) (0)
Abstract B69: Evaluation of Src-mediated signaling events in pancreatic cancer. (2012) (0)
Abstract LB-217: CK2 protein kinase promotes resistance to MAPK pathway inhibition (2014) (0)
Abstract 1075: Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer (2023) (0)
Filling in the GAPs in understanding RAS. (2021) (0)
Inhibition of RalB geranylgeranylation is required for GGTI suppression of proliferation and induction of apoptosis (2006) (0)
RAS Oncoproteins: Therapeutic Vulnerabilities (2018) (0)
Abstract 3129: Regulation of expression and role of the pigment epithelium derived factor in Ras-mediated pancreatic oncogenesis (2010) (0)
A sensitized screen for identifying inhibitors of EGF vulval induction activity (2010) (0)
GTPases. Alan Hall (2001) (0)
Computational design of chemogenetic and optogenetic split proteins (2018) (0)
Cloning of Novel Oncogenes Involved in Human Breast Cancer (2002) (0)
Activation of Phospholipase C- (cid:1) by Heterotrimeric G Protein (cid:2)(cid:3) -Subunits* (2001) (0)
Iconographies supplémentaires de l'article : Are all KRAS mutations created equal? (2011) (0)
Faculty Opinions recommendation of The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. (2015) (0)
Effectors of Ras-Mediated Oncogenesis (2006) (0)
Abstract LB-276: Farnesyltransferase inhibitor (FTI)-induced growth inhibition of HRAS-mutant head and neck cancers is enhanced by concurrently inhibiting compensatory upregulation of the ERK-MAPK kinase cascade (2019) (0)
Abstract PR07: Transcriptome meta-analysis identifies new 5-gene classifier for early detection of pancreatic cancer (2015) (0)
Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers (2022) (0)
Phosphatidylinositol 3-Kinase Signaling Immortalized Human Pancreatic Cells by Raf and KRas Promotes Growth Transformation and Invasion of Updated (2007) (0)
Validation of Isoform- and Mutation-Specific RAS Antibodies. (2021) (0)
Abstract PR10: Enhancing the effect of autophagy inhibition for pancreatic cancer treatment (2019) (0)
2 D ec 2 00 3 New High Field State of Flux Line Lattice in Unconventional Superconductor CeCoIn (0)
Mechanisms of Rerg-Mediated Tumor Suppression in Breast Cancer (2008) (0)
GTPases involved in vesicular traffic (2001) (0)
Abstract IA12: Targeting KRAS-regulated metabolic activities in pancreatic cancer (2020) (0)
Abstract LB-30: A functional analysis of the nuclear RhoGEF Ect2 in ovarian cancer (2012) (0)
Faculty Opinions recommendation of Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. (2013) (0)
Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer (2021) (0)
Guanine Nucleotide Exchange Region of Intersectin in Complex with Cdc42 (2002) (0)
Abstract C15: Therapeutic benefit of targeting ERK in mutant KRAS in pancreatic ductal adenocarcinoma (PDAC) (2013) (0)
Tumor suppressor mediated ubiquitylation of hnRNPK is a barrier to oncogenic translation (2022) (0)
Faculty Opinions recommendation of The consensus coding sequences of human breast and colorectal cancers. (2006) (0)
Faculty Opinions recommendation of Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. (2004) (0)
Abstract LB-276: Application of a CRISPR/Cas9 screen to identify novel therapeutic strategies with CDK4/6 inhibitors in pancreatic cancer (2018) (0)
Abstract A08: Mechanistic dissection of Ral GTPase signaling in driving KRAS-dependent pancreatic cancer growth (2014) (0)
G-proteins | Small GTPases (2021) (0)
Abstract B009: TEAD inhibition overcomes YAP1/TAZ-driven resistance to RAS inhibitors in KRASG12C-mutant cancers (2023) (0)
Faculty Opinions recommendation of Ras signalling on the endoplasmic reticulum and the Golgi. (2002) (0)
Faculty Opinions recommendation of A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. (2006) (0)
Faculty Opinions recommendation of Yersinia virulence depends on mimicry of host Rho-family nucleotide dissociation inhibitors. (2006) (0)
VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer (2023) (0)
CHAPTER 234 – Role of R-Ras in Cell Growth (2003) (0)
Abstract B48: Pancreatic cancer cells exhibit heterogeneous glucose and glutamine metabolic dependencies (2015) (0)
RHOA mutations in cancer: Oncogenes or tumor suppressors? (2017) (0)
Role of NF1 and NF2 in Signaling and Transformation (1999) (0)
579 POSTER Biological and biochemical activity of TLN-4601 in pancreatic cancer (2008) (0)
Farnesylated proteins: how do they get to where they need to go, and how does location regulate their ability to control proliferation, death, transformation and aging? (2006) (0)
Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treatKRAS-mutant pancreatic cancer (2019) (0)
Abstract C188: RalA phosphorylation as a biomarker in pancreatic ductal adenocarcinoma for Aurora A kinase inhibition in response to the investigational agent MLN8237. (2011) (0)
Extended characterization of MCP110, an inhibitor of Ras-dependent signaling: Mode of action and preclinical analysis (2004) (0)
RAS Genes and Cancer (2014) (0)
Faculty Opinions recommendation of RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. (2010) (0)
Peptides containing a consensus Ras binding sequence from Raf-1 and the GTPase activating protein NF 1 inhibit Ras function ( mitogen-activated protein kinase / signal transduction / transformation ) (2005) (0)
TITLE : Cloning of Novel Oncogenes Involved in Human Breast Cancer PRINCIPAL INVESTIGATOR : (0)
Crystal Structure of the Dbl and Pleckstrin homology domains of Dbs in complex with RhoA (2002) (0)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer (2019) (0)
Abstract B147: P-Rex1 is required for efficient melanoma metastasis. (2011) (0)
Abstract IA06: Targeting the ERK-MYC signaling network for the treatment of KRAS-mutant cancers (2023) (0)
Cancer Biology and Signal Transduction Response to MLN 8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation (2013) (0)
Faculty Opinions recommendation of Germline gain-of-function mutations in SOS1 cause Noonan syndrome. (2007) (0)
Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma (2022) (0)
Abstract A25: Evaluating a role for Rac1-PAK1 signaling in promoting the growth of KRAS-mutant pancreatic cancer (2014) (0)
Abstract 3829: Preclinical development of a combination inhibitor strategy to block K-Ras effector signaling and autophagy for pancreatic cancer treatment (2016) (0)
PHA / PMA-Stimulated Jurkat Cells-raf-MEK-ERK Cascade in ras p 21 Regulation of Lymphotoxin Production (1999) (0)
Abstract A54: Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma (2020) (0)
Abstract 4660: Inhibition of p38 enhances ERK inhibitor efficacy in pancreatic ductal adenocarcinoma (2016) (0)
582 POSTER Analysis of small molecule Ras/Raf interaction inhibitors in C. elegans identifies both on-target and off-target activities (2006) (0)
Therapeutics , Targets , and Chemical Biology ROCK 1 and ROCK 2 Are Required for Non-Small Cell Lung Cancer Anchorage-Independent Growth and Invasion (2012) (0)
Abstract B034: Determination of KRAS- and ERK-regulated phosphoproteomes in KRAS-mutant cancers (2023) (0)
The Carboxyl-terminal CXXX Sequence of Gia, but Not Rab5 or R a b l l , Supports Ras Processing and Transforming Activity* (2001) (0)
MEK ERK CRAF Tumor growth Tumor progression Tumor regression Tumor growth = Vemurafenib Drug-induced acquired tumor resistance Drug-induced tumor progression (2012) (0)
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer (2020) (0)
Retraction Notice to: RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress (2019) (0)
Faculty Opinions recommendation of Identification of a bacterial type III effector family with G protein mimicry functions. (2006) (0)
Genome-wide DNA methylation analysis of KRAS mutant cell lines (2020) (0)
Abstract A137: Drug screening and molecular profiling identifies INKA1 as a predictive biomarker for sensitivity to MAPK inhibition-antimitotic combination treatment in pancreatic ductal adenocarcinoma (2019) (0)
Abstract B31: Combination inhibitor strategies targeting KRAS effector signaling in KRAS-mutant pancreatic cancer (2020) (0)
Rigaud and Schmincke Types of Lymphoepithelioma (2011) (0)
Neurons and Nonneuronal Cells in Components of the Endocytic Machinery Splice Variants of Intersectin Are CELL BIOLOGY AND METABOLISM (2013) (0)
Blocking autophagy to starve pancreatic cancer (2019) (0)
Novel Oncogenes in Breast Cancer Development (2001) (0)
Abstract A29: The gastric cancer-associated mutations R5W and Y42C in the RAS homologous RHOA protein cause distinct biochemical alterations, exhibit gain-of-function signaling and oncogenic activities (2020) (0)
Filling in the GAPs in understanding RAS: A newly-identified regulator increases the efficacy of a new class of targeted anti-RAS drugs (2021) (0)
Abstract 4458: Regulation of MYC protein stability by mutant KRAS in pancreatic ductal adenocarcinoma (2017) (0)
Ras Stories: The State of the Art (2006) (0)
RHO Proteins in RAS Signaling and Transformation (2006) (0)
QS282. BRAF Mutation Status, But not ERK Activation, Is Predictive of Response to the MEK Inhibitor AZD6244 in Colorectal Cancer (2008) (0)
Abstract C152: Mechanisms of KRAS dependency in pancreatic ductal adenocarcinoma. (2011) (0)
Abstract B40: Role of mutant HRAS in growth and drug sensitivity of head and neck squamous cell cancers (HNSCC) (2020) (0)
Engineering threshold-based selection systems (2021) (0)
Abstract IA08: Drugging undruggable kras: will myc do the trick? (2016) (0)

This paper list is powered by the following services:

Other Resources About Channing Der

en.wikipedia.org

What Schools Are Affiliated With Channing Der?

Channing Der is affiliated with the following schools:

Channing Der's Academic­Influence.com Rankings